Industry News-Good Doctor

Blog

——

2025.04.29

Good Doctor. Hot Infusion | Reprint 3: List of Upcoming Events, including the 9th Indian Society of Peritoneal Surface Oncology (INDEPSO)

9th Annual INDEPSO-ISPSM Peritoneal Malignancy Advances Symposium

2025.04.29

Good Doctor. Hot Infusion | Reprint 2: Progress and achievements of PSOGI/PSM certified centers of excellence. Milan Cancer Institute's contribution to peritoneal oncology: Past, present and future

In the mid-1990s, the Italian National Cancer Institute (Fondazione IRCCS Istituto Nazionale dei Tumori) in Milan established a Peritoneal Surface Malignancies (PSM) program, becoming one of the pioneering centers for peritoneal tumors in Europe. After completing surgical training in Washington, D.C. with Dr. Paul Sugarbaker, Marcello Deraco assembled a specialized team to treat peritoneal malignancies, which were then considered largely incurable. At the time, systemic chemotherapy was considered to have limited efficacy against peritoneal malignancies, and surgery was viewed as purely palliative.

2025.04.29

Good Doctor. Hot Infusion | Reprint 1: Clinical or laboratory research progress -- Small bowel transplantation for pseudomyxoma peritonei

Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by mucinous ascites, peritoneal implants, and the formation of omental cakes. The vast majority of PMP originates from perforation of appendiceal mucinous tumors, while a minority originates from other organs such as the ovaries, umbilical cord, colon, and pancreas. Perforation of mucinous tumors leads to the shedding of mucin and mucin-producing epithelial cells into the peritoneal cavity. Through redistribution, it spreads sequentially to the right paracolic gutter, right subphrenic space, left subphrenic space (including the spleen), greater omentum, and pelvic floor (including the ovaries and uterus in females) [Carr NJ et al., Am J Surg Pathol. 2016]. PMP usually progresses slowly and rarely metastasizes to lymph nodes or distant sites.

2025.04.07

Forwarding: Quality Control Considerations for Intraperitoneal Hyperthermic Chemotherapy: How to Avoid Instability in Perfusion

For peritoneal carcinomatosis or malignant ascites, hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard approach. Of course, some patients undergo cytoreductive surgery (CRS) before HIPEC to reduce tumor burden and even achieve radical resection of organs affected by the tumor for better efficacy. Here, we focus on infusion instability.

2025.04.07

Repost: CRS+HIPEC can still be performed and benefit patients even if there is extraperitoneal tumor involvement.

2024.09.12

How to differentiate between cancerous and non-cancerous ascites

A normal person's abdominal cavity contains only a small amount of fluid, which lubricates the internal organs. When the amount of fluid in the abdominal cavity increases to more than 200 ml, it is called ascites. This article describes the diagnostic and therapeutic characteristics and treatment methods of different types of ascites, aiming to help more clinicians better understand and manage this clinical problem.

2018.11.22

The supply and demand environment continues to improve, and leading medical device companies are expected to benefit from import substitution.

The National Health Commission recently released the "Large Medical Equipment Configuration Plan for 2018-2020," proposing that by the end of 2020, a total of 22,548 large medical devices will be planned for configuration nationwide, including 10,097 new devices to be implemented over three years. The overall planned configuration of proton therapy tumor systems nationwide is controlled to be within 10 units.

2018.11.22

Closer to the goal of early cancer screening

The 6th National Cancer Center Academic Annual Conference was recently held. Reporters learned from the conference that key national research and development program projects and several international cooperation projects are accelerating their layout in this field. At the same time, four national-level cancer screening projects that have been ongoing for more than a decade are also continuously adding new technological elements.

< 1 2 3 4 5 > proceed page

· GDHIPEC from China ,

· Caring for Patients Worldwide ·

Tel.: +86 29 82681864

Sales service hotline: +86 15002902555

E-mail: gd029@126.com

Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143

Blog

COOKIES

COOKIES

Sorry，The current column has no content!